Many drugs, or their antecedents, were discovered through observation of their effects on
normal or disease physiology. For the past generation, this phenotypic drug discovery …

Highlights•Artificial Intelligence (AI) has transformed many areas such as speech and image
recognition, but not yet drug discovery.•Approaches to AI in drug discovery need to take in …

Bone defects repair and regeneration by various causes such as tumor resection, trauma,
degeneration, etc. have always been a key issue in the clinics. As one of the few organs that …

Cancer immunotherapies have shown substantial clinical activity for a subset of patients with
epithelial cancers. Still, technological platforms to study cancer T-cell interactions for …

Receptor tyrosine kinase signalling pathways have been successfully targeted to inhibit
proliferation and angiogenesis for cancer therapy. However, kinase deregulation has been …

Environmental factors are the largest contributors to cardiovascular disease. Here we show
that cardiac organoids that incorporate an oxygen-diffusion gradient and that are stimulated …

G protein-coupled receptors (GPCRs) are the largest class of receptors in the human
genome and some of the most common drug targets. It is now well established that GPCRs …

Cancer cell metabolism is heavily influenced by microenvironmental factors, including
nutrient availability. Therefore, knowledge of microenvironmental nutrient levels is essential …

Phenotypic drug discovery (PDD) approaches do not rely on knowledge of the identity of a
specific drug target or a hypothesis about its role in disease, in contrast to the target-based …

Drug repurposing holds the potential to bring medications with known safety profiles to new
patient populations. Numerous examples exist for the identification of new indications for …